![Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study - The Lancet Oncology Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study - The Lancet Oncology](https://www.thelancet.com/cms/attachment/92e12243-872b-45e2-900f-20433369d7f8/gr1.gif)
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study - The Lancet Oncology
![Pomalyst (Pomalidomide) Received a New Indication for Patients with Relapsed and/or Refractory Multiple Myeloma Pomalyst (Pomalidomide) Received a New Indication for Patients with Relapsed and/or Refractory Multiple Myeloma](https://jhoponline.com/images/jhop/2016/JHOPPayersGuide/JHOP_March2016_SpecialEdition_Vol6_Pg83_Tbl1_efficacy_results_MM-003.png)
Pomalyst (Pomalidomide) Received a New Indication for Patients with Relapsed and/or Refractory Multiple Myeloma
![Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers | Journal of Cancer Research and Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers | Journal of Cancer Research and](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00432-020-03323-6/MediaObjects/432_2020_3323_Fig1_HTML.png)
Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers | Journal of Cancer Research and
![Phase II Trials of Pomalidomide and Dexamethasone in Combination with Either Cyclophosphamide or Bortezomib in Relapsed or Refractory MM | Research To Practice Phase II Trials of Pomalidomide and Dexamethasone in Combination with Either Cyclophosphamide or Bortezomib in Relapsed or Refractory MM | Research To Practice](http://www.researchtopractice.com/sites/default/files/imagecache/slideshow_image/5mjc/slides/2011/5MJCASH2015/2/4/Slide04.jpg)
Phase II Trials of Pomalidomide and Dexamethasone in Combination with Either Cyclophosphamide or Bortezomib in Relapsed or Refractory MM | Research To Practice
![Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma | Research To Practice Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma | Research To Practice](http://www.researchtopractice.com/sites/default/files/imagecache/slideshow_image/5mjc/slides/2011/5MJCASH2013/5/6/Slide03.jpg)
Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma | Research To Practice
![PDF] Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. | Semantic Scholar PDF] Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/be4724496d6a2bc3c1ce363734069c2dc2a77f30/2-Figure1-1.png)
PDF] Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. | Semantic Scholar
![Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial - The Lancet Oncology Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/asset/89c8d31b-cfa4-470f-a4e1-c19f5228c2de/gr1.gif)
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial - The Lancet Oncology
![The real‐world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies - Szabo - eJHaem - Wiley Online Library The real‐world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies - Szabo - eJHaem - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/581c89ed-2150-4a3b-89d0-39fea490866c/jha2774-gra-0001-m.jpg?trick=1692952399923)
The real‐world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies - Szabo - eJHaem - Wiley Online Library
![Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial | Blood Cancer Journal Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial | Blood Cancer Journal](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41408-021-00593-2/MediaObjects/41408_2021_593_Fig1_HTML.png)
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial | Blood Cancer Journal
![Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial - The Lancet Haematology Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial - The Lancet Haematology](https://www.thelancet.com/cms/attachment/f4bdf9bb-a203-42c5-ad4d-097573ca90b9/gr1.gif)
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial - The Lancet Haematology
![PDF] Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. | Semantic Scholar PDF] Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/c2d9ab11b5739b401b8d3d2d135f5d895e4a8519/14-Figure3-1.png)
PDF] Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. | Semantic Scholar
![Maintenance therapy with carfilzomib, pomalidomide, and dexamethasone (KPd) in high-risk myeloma pts - YouTube Maintenance therapy with carfilzomib, pomalidomide, and dexamethasone (KPd) in high-risk myeloma pts - YouTube](https://i.ytimg.com/vi/bfwMJ2dfVHI/maxresdefault.jpg)
Maintenance therapy with carfilzomib, pomalidomide, and dexamethasone (KPd) in high-risk myeloma pts - YouTube
![Pomalidomide/Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma | Research To Practice Pomalidomide/Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma | Research To Practice](http://www.researchtopractice.com/sites/default/files/imagecache/slideshow_image/5mjc/slides/2011/Browse-tumor-types/heme/5mjc_ASH/24/Slide3.jpg)
Pomalidomide/Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma | Research To Practice
Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma | Haematologica
![Pomalidomide, Bortezomib, and Dexamethasone (PVd) for Chinese Multiple Myeloma Patients at First Relapse - ScienceDirect Pomalidomide, Bortezomib, and Dexamethasone (PVd) for Chinese Multiple Myeloma Patients at First Relapse - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497121066763-gr1.jpg)
Pomalidomide, Bortezomib, and Dexamethasone (PVd) for Chinese Multiple Myeloma Patients at First Relapse - ScienceDirect
![Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial - The Lancet Oncology Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/3f9a805c-3a94-4d62-8327-94885008b803/gr1.gif)